Dental Practice Valuation Multiples in Texas (2026)

A general-practice dental office in Texas sells for one of two completely different prices in 2026, and which one you get depends entirely on who signs the check. Sell to another dentist and you'll price at 60% to 85% of collections, or 1.5x to 2.5x seller's discretionary earnings, according to Dental Transitions. Sell to a DSO or a private-equity-backed group and you're priced off adjusted EBITDA instead: 5x to 7x if your adjusted EBITDA is under $1M, 7x to 9x at $1M to $3M, 9x to 11x at $3M to $5M, and 11x or better once you're a platform-grade practice above $5M, per FOCUS Investment Banking data compiled by Sorso in December 2025.

Most Texas owners reading this are in the first band. That's not bad news. It just means the single biggest lever on your sale price isn't the multiple you negotiate, it's the EBITDA number you hand the buyer, and you have two to three years to change that number before anyone runs a quality-of-earnings analysis on you.

What Texas Practices Actually Trade For in 2026

Stack the two published multiple sets side by side and the ranges line up more than you'd expect. Dental Transitions puts DSO and PE add-on purchases at 5x to 8x EBITDA, regional DSO and PE platforms at 9x to 11x, and large PE-backed platforms at 10x to 12x and up. Sorso's FOCUS-sourced numbers organize the same market by size rather than buyer type and land in the same territory. The takeaway from both: nobody pays a platform multiple for a single-location practice, and nobody pays a 5x add-on multiple for a four-location group doing $4M of EBITDA.

Specialty matters too. Sorso reports specialty practices command 1 to 3 additional turns of EBITDA over general dentistry at comparable size. If you own an oral surgery or ortho practice in Dallas or Houston with $1.5M of adjusted EBITDA, you're realistically shopping a 9x to 11x conversation, not a 7x to 9x one. That gap is worth more than most owners' entire retirement account.

One thing to be honest about: neither of those sources publishes a Texas-specific multiple. There isn't a credible public dataset that says "Texas general practices trade at X.Yx. What exists is national multiple data plus Texas-specific supply and regulatory facts that push demand in a direction. Anyone quoting you a precise Texas-only multiple is quoting their own deal book, which may be four transactions deep. Ask how many.

Why Texas Prices Above the National Average

Texas is short on dentists. The state has 54.2 dentists per 100,000 population against 59.5 nationally as of 2024, per ADA figures cited by Peony. That's roughly a 9% practitioner shortfall relative to the country, in a state adding population faster than almost anywhere else.

For a seller, undersupply does two useful things. It keeps chairs full, which protects collections and makes your revenue trend defensible in diligence. And it thins out the competing-supply problem on the buy side: a DSO expanding into the Texas market has fewer acquisition targets per capita to choose from, which is exactly the condition that gets you a competitive process instead of a single letter of intent.

The national labor picture backs this up. The Bureau of Labor Statistics projects dentist employment growing 6% from 2025 to 2035, adding about 9,000 jobs to a base of 161,400. Six percent over a decade is steady, not explosive. New dentists are not going to flood the Texas market and compete your valuation down inside your exit window.

Two Buyers, Two Formulas, Two Very Different Closings

The percentage-of-collections formula and the EBITDA formula aren't just different math. They're different transactions.

• Doctor-to-doctor. Priced at 60% to 85% of collections or 1.5x to 2.5x SDE per Dental Transitions. Usually all cash at close or bank-financed. You walk. The buyer takes over your chair. Simple, fast, and capped: collections-based pricing rewards top-line volume and completely ignores how well you run the place.
• DSO or PE. Priced off adjusted EBITDA at the size bands above. Almost always includes an equity rollover, a post-close employment term of two to five years, and an earnout or holdback. The headline number is bigger. The cash at close is often 60% to 80% of it, with the rest riding on the platform's performance.

Here's the part owners miss: a well-run practice is worth dramatically more to the EBITDA buyer, and a sloppy-but-busy practice is often worth more to the dentist buyer. If your overhead runs 70% and your collections are strong, percentage-of-collections flatters you. If your overhead runs 55%, the EBITDA formula pays you for that discipline and the collections formula does not. Know which side of that line you're on before you pick a broker.

The Margin Squeeze Sitting Under Every Multiple

The reason EBITDA has become the pricing metric is that dental margins have been going the wrong direction. Over the past five years, practice revenue rose just 1.4% while expenses rose 4.9%, according to the ADA Health Policy Institute. That's a 3.5-point spread compounding against owner earnings, and it lands directly on the number your valuation gets multiplied against.

Buyers know this. It's why diligence now digs into supply cost per procedure, staff cost as a percentage of collections, and PPO write-off trends rather than just three years of tax returns. A practice with flat collections and rising overhead is a practice with shrinking EBITDA, and a shrinking EBITDA gets a discount on the multiple on top of the smaller base. That's the double penalty.

SB 1318 Changed What Your Buyer Can Ask For

Texas SB 1318 took effect September 1, 2025, and it caps physician and dentist non-compete buyouts at one year of the practitioner's salary and wages, with the restricted radius limited to five miles, as documented by Peony. Separately, Texas Business and Commerce Code Chapter 73 has required DSOs to register annually with the Secretary of State since 2015.

Two practical consequences for a 2026 seller. First, the five-mile cap and the one-year buyout ceiling limit how much a buyer can lock you down after close, which cuts both ways: it protects your future optionality, and it slightly raises the buyer's perceived risk that you'll compete, so expect longer employment terms and bigger holdbacks to compensate. Second, the Chapter 73 registration requirement is a free diligence tool pointed the other direction. Before you sign an LOI, check whether the DSO courting you is actually registered with the Texas Secretary of State. If they aren't, that tells you something about their compliance discipline and their appetite for paperwork, and you're about to be a line item in their paperwork for the next five years.

Operator Math

Take a single-location Texas general practice collecting $1,400,000 a year with total operating expenses, before any owner compensation, running 62% of collections. Expenses come to $868,000.

That leaves $532,000 of pre-owner-compensation profit, which is also the seller's discretionary earnings figure a dentist buyer would work from.

Now convert to adjusted EBITDA the way a DSO will. Say the owner personally produces $1,100,000 of the $1,400,000, with hygiene covering the rest. Replacing the owner with an associate at 30% of doctor production costs $330,000.

Adjusted EBITDA is therefore $202,000.

That lands in the under-$1M band, so 5x to 7x applies. At 6x, the DSO price is $1,212,000.

Compare the dentist buyer at 75% of collections, the midpoint of the 60% to 85% range: $1,050,000.

Or the SDE method at 2.0x on $532,000: $1,064,000.

So the DSO route is worth about $162,000 more on paper than the dentist-buyer route in this scenario, before you account for rollover equity and the five-year employment commitment attached to it.

Now the part that actually pays. Cut overhead by three points, from 62% to 59%, and you add $42,000 of annual EBITDA.

At the same 6x, that three-point overhead improvement is worth $252,000 of enterprise value.

Three points of overhead. A quarter of a million dollars at close. That is the highest-return project available to any practice owner planning an exit inside three years, and it costs nothing but attention to supply contracts, staffing ratios, and your worst PPO plans.

Scale compounds it. Grow to a small group with $1,100,000 of adjusted EBITDA and you move into the $1M to $3M band at 7x to 9x. At 8x, that's $8,800,000.

EBITDA grew 5.4x. Enterprise value grew 7.3x. The extra 1.9 turns of multiple expansion is what the band structure pays you for getting bigger.

Working Capital Is a Valuation Line Item, Not a Cash Flow Problem

It belongs in a valuation article, because the two are the same conversation.

With revenue up 1.4% against expenses up 4.9% per the ADA HPI, the gap gets funded somewhere: a line of credit, delayed equipment replacement, stretched vendor terms, or the owner's own distributions. Every one of those shows up in diligence. Deferred capex means the buyer reprices for the chairs and sensors you didn't replace. A drawn-down credit line means a working capital adjustment at close that comes out of your proceeds. Stretched payables means the buyer normalizes your expenses upward, which lowers adjusted EBITDA, which gets multiplied by 6.

Fund working capital deliberately two years before you sell, and it's an operating decision. Fund it by starving the practice, and it's a discount on your multiple.

What Actually Moves Your Multiple

Size band is the biggest factor, and it's the one you can change: crossing from under $1M to over $1M of adjusted EBITDA is worth roughly two extra turns. Specialty mix is worth 1 to 3 turns per Sorso. Associate coverage matters because a practice where the owner produces 80% of collections has a replacement-cost problem baked into its adjusted EBITDA, exactly as the math above shows. Clean books, real provider-level production reporting, and a documented hygiene program are table stakes now, not differentiators. And buyer type sets the ceiling: the same practice shopped only to dentists will never see a 9x conversation, regardless of how well it runs.

The Takeaway

Calculate your adjusted EBITDA the way a buyer will, with an associate replacement cost subtracted for your own production, before you talk to anyone. If that number is under $1M, spend the next 24 months cutting overhead points and adding provider capacity rather than negotiating multiples, because three overhead points is worth about $252,000 of enterprise value at 6x on a $1.4M practice. Decide deliberately whether you're selling to a dentist at 60% to 85% of collections or to a DSO at an EBITDA multiple, because the two reward completely different operating behavior. And verify any DSO courting you is registered under Texas Business and Commerce Code Chapter 73 before you sign a thing.

If you don't know your adjusted EBITDA or which size band you'd fall into, that's the number to get straight first. The Dental Signal valuation calculator takes your collections, overhead percentage, and owner production split and returns your adjusted EBITDA, the multiple band it falls in, and the corresponding collections-based price a dentist buyer would offer, so you can see the gap between the two exit paths before a broker frames it for you. Run your own numbers and find out which side of the $1M EBITDA line you're actually on.